1. Home
  2. NXL vs ALUR Comparison

NXL vs ALUR Comparison

Compare NXL & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

N/A

Current Price

$0.81

Market Cap

18.6M

Sector

Health Care

ML Signal

N/A

ALUR

Allurion Technologies Inc.

N/A

Current Price

$1.48

Market Cap

15.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NXL
ALUR
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
15.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NXL
ALUR
Price
$0.81
$1.48
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$5.00
$9.25
AVG Volume (30 Days)
118.5K
113.0K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$156,931.00
$17,208,000.00
Revenue This Year
$38.28
N/A
Revenue Next Year
$185.71
$9.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$1.02
52 Week High
$4.09
$16.81

Technical Indicators

Market Signals
Indicator
NXL
ALUR
Relative Strength Index (RSI) 31.04 45.33
Support Level $0.80 $1.46
Resistance Level $1.01 $1.71
Average True Range (ATR) 0.06 0.12
MACD -0.01 0.01
Stochastic Oscillator 2.73 38.47

Price Performance

Historical Comparison
NXL
ALUR

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Share on Social Networks: